Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE
Description This study will be in downtown Buffalo and Williamsville

Objective A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Principal Investigator SZIGETI, KINGA
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT02670083/
Status Not Open
Key Eligibility Ages 50-85
Alzheimer's Disease
Disease Group Alzheimer's/Dementia
Treatment crenezumab
Contact CONNIE BRAND
716-859-7540
conniebr@buffalo.edu